Skip to content

    Innova Captab Q4 FY26 earnings call

    INNOVACAP
    Healthcare·8 May 2026
    Management Summary

    Innova Captab delivered strong Q4 and FY26 results, achieving its highest-ever annual performance with significant revenue growth across both CDMO and Branded Generics segments. The Jammu facility is nearing profitability, and the company has strategic capex plans for a new Baddi facility to support future growth. While product mix impacted Q4 margins, management expects overall margin expansion and outperformance of PAT growth over EBITDA growth in the coming fiscal year.

    Highlights

    5

    • Consolidated revenue for Q4 FY26 stood at ₹447.8 crores, marking a strong 42% year-on-year growth.

    • FY26 consolidated revenue reached ₹1,630 crores, a healthy growth of 31% year-on-year, driven by both CDMO and Branded Generics segments.

    • CDMO business reported ₹1,133 crores revenue in FY26, growing 24% YoY, while Branded Generics grew 51% YoY to ₹497 crores.

    • The Jammu facility, which contributed ₹300 crores in FY26, is expected to become EBITDA positive in the coming quarter (Q1 FY27).

    • Regulatory milestones achieved with UK-MHRA approval for Baddi cephalosporin facility and PIC/S certification for Jammu blocks, enhancing international market access.

    Concerns

    2

    • Q4 EBITDA margin was 14.9%, a decline from the FY26 operating margin of 15.4%, primarily due to a change in product mix.

    • API prices have seen a 'certain uptick' due to the Middle East situation, though the company's cost-plus model allows for pass-through to customers.

    Key financials

    Metrics

    8

    Periods

    2

    Q4 FY26

    4
    • Revenue
      ₹447.8 Cr
      YoY+42%
    • EBITDA
      ₹66.7 Cr
      YoY+31%
    • EBITDA Margin
      14.9%
    • PAT
      ₹38.1 Cr
      YoY+29.0%

    FY26

    4
    • Revenue
      ₹1,630 Cr
      YoY+31%
    • EBITDA
      ₹250.3 Cr
      YoY+26.3%
    • Operating Margin
      15.4%
    • PAT
      ₹140.9 Cr
      YoY+10%

    Segment breakdown

    • CDMO Business₹1,133 Cr52.2%
    • Branded Generics Business₹497 Cr22.9%
    • Jammu Facility₹300 Cr13.8%
    • Sharon Bio (Acquired Entity)₹240 Cr11.1%
    Donut· Share of Revenue (FY26)

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹150 crores

    M&A

    Sharon Bio

    acquisition · integrated

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    Overall Revenue Growth
    20% plus
    		High
    Revenue
    New Baddi Plant Revenue Potential
    INR450-500 crores
    		Medium
    Profitability
    EBITDA Growth vs Revenue Growth
    outperform revenue growth
    		High
    Profitability
    PAT Growth vs EBITDA Growth
    outpace EBITDA growth
    		High
    Profitability
    Jammu Facility EBITDA Status
    EBITDA positive
    		High
    Capex
    New Baddi Plant Capital Outlay
    INR150-170 crores
    		High
    Volume
    Overall Volume Growth
    20% plus
    		High

    What to watch in Q1 FY27

    4

    Jammu Facility EBITDA Positivity

    Q1 FY27
    CurrentNearing EBITDA in Q4 FY26
    TargetEBITDA positive and covering fixed costs

    Why it matters

    Key indicator of the successful ramp-up and profitability contribution from the new Jammu facility.

    And in coming quarter, as we said that the Jammu ramp-up is going on. We are very much positive that in coming quarter, we should be able to achieve EBITDA positive as well as start covering the fixed cost on Jammu part.

    Risks & concerns

    2
    RiskSeverity

    API Price Volatility

    Certain uptick in raw material prices due to Middle East situation, though largely passed on through cost-plus model. — Management acknowledged

    medium

    Gross Margin Compression due to Product Mix

    Q4 gross margin decline was mainly due to a change in product mix, not raw material costs. — Management acknowledged

    low

    Q&A highlights

    8

    “So yes, so due to this going on conflict, there is certain uptick in prices of our raw materials and major ingredients. You rightly said, our cost our pricing with CDMO's customers on cost-plus basis. So largely, those increase has been passed to our customers.”

    Clarifies that while API prices are rising, the company's cost-plus model allows them to pass on increases, mitigating margin risk.

    asked by Anubhav

    2 min read6 chapters

    Detailed Narrative

    01

    Robust Q4 and FY26 Financial Performance

    Innova Captab delivered strong financial results, with consolidated revenue growing 42% year-on-year to ₹447.8 crores in Q4 FY26 and 31% year-on-year to ₹1,630 crores for the full FY26. Both the CDMO and Branded Generics segments were key contributors, growing 41% and 46% respectively in Q4, and 24% and 51% for the full year. The company achieved an EBITDA of ₹66.7 crores in Q4, up 31% YoY, and ₹250.3 crores for FY26, with an operating margin of 15.4%.

    02

    Jammu Facility Ramp-up and Path to Profitability

    The Kathua facility in Jammu successfully completed its first full year of operation, contributing approximately ₹300 crores in revenue for FY26, with a Q4 exit run rate exceeding ₹90 crores. Management indicated the facility was 'nearing EBITDA' in Q4 and is confidently expected to achieve EBITDA positive status in the coming quarter (Q1 FY27). This milestone will enable the facility to start covering its fixed costs, significantly contributing to overall profitability.

    03

    Strategic Capacity Expansion at Baddi

    To address high utilization rates at its existing Baddi facilities and expand its general portfolio, Innova Captab plans a new oral tablet, capsule, and liquid facility. This project involves a capital outlay of ₹150-170 crores, to be incurred over FY27 and FY28. This new block is projected to generate ₹450-500 crores in revenue at optimum utilization, highlighting its importance for sustaining future growth momentum and diversifying manufacturing capabilities.

    04

    Regulatory Achievements and International Market Focus

    The company achieved significant regulatory milestones, including UK-MHRA approval for its cephalosporin facility in Baddi and PIC/S certification for its Jammu blocks. These certifications are crucial for supporting entry into regulated international markets and strengthening Innova Captab's positioning. The acquisition of Sharon Bio, which contributed approximately ₹240 crores in FY26 revenue with a better-than-average EBITDA margin, further enhances the company's presence in markets like Canada, UK, Europe, and Australia.

    05

    Future Margin Trajectory and Operational Leverage

    While Q4 gross margins saw a slight decline primarily due to product mix changes, management anticipates overall margin expansion in the future. They expect EBITDA growth to outperform revenue growth, and PAT growth to outpace EBITDA growth. This improvement is driven by operational leverage from increasing scale and the capitalization of interest and depreciation costs associated with new facilities, with the company's cost-plus model effectively mitigating rising raw material prices.

    06

    Diversified Growth Strategy and Semaglutide Plans

    Innova Captab maintains a diversified growth strategy across its CDMO and Branded Generics businesses, with exports contributing 31% to FY26 revenue. Both segments are well-diversified by customer and geography, reducing concentration risk. The company is also actively working on a 'wave 2 type concept' for high-growth segments like Semaglutide, indicating a strategic approach to capitalize on emerging market opportunities after initial product launches.

    This is an AI-generated summary of a publicly available earnings call transcript.